The U.S. Food and Drug Administration (FDA) recently approved the use of a new treatment (or disease-modifying therapy) called aducanumab for Alzheimer’s disease.
This medication is now being evaluated by Health Canada. A group of dementia researchers and clinicians have reviewed the available information and concluded that more testing is required before aducanumab is approved in Canada.
The full statement by this group, as well as a summary of the statement prepared for the general public, can be found here: